**S1 Table.** Patient characteristics according to risk group in the investigation dataset

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Investigation dataset</th>
<th>Risk group</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Total (n=340)</td>
<td>Low (n=147)</td>
<td>Intermediate (n=145)</td>
</tr>
<tr>
<td>Age (yr)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>&lt; 67</td>
<td>163 (47.9)</td>
<td>75 (51)</td>
<td>67 (46.2)</td>
</tr>
<tr>
<td>≥ 67</td>
<td>177 (52.1)</td>
<td>72 (49)</td>
<td>78 (53.8)</td>
</tr>
<tr>
<td>Sex</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Male</td>
<td>201 (59.1)</td>
<td>86 (58.5)</td>
<td>83 (57.2)</td>
</tr>
<tr>
<td>Female</td>
<td>139 (40.9)</td>
<td>61 (41.5)</td>
<td>62 (42.8)</td>
</tr>
<tr>
<td>Disease status</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Recurrent</td>
<td>117 (34.4)</td>
<td>71 (48.3)</td>
<td>37 (25.5)</td>
</tr>
<tr>
<td>Metastatic</td>
<td>223 (65.6)</td>
<td>76 (51.7)</td>
<td>108 (74.5)</td>
</tr>
<tr>
<td>ECOG</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>0-2</td>
<td>296 (87.1)</td>
<td>147 (100)</td>
<td>144 (99.3)</td>
</tr>
<tr>
<td>3-4</td>
<td>44 (12.9)</td>
<td>0</td>
<td>1 (0.7)</td>
</tr>
<tr>
<td>Primary site</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Intrahepatic CC</td>
<td>87 (25.6)</td>
<td>30 (20.4)</td>
<td>37 (25.5)</td>
</tr>
<tr>
<td>Hilar CC</td>
<td>56 (16.5)</td>
<td>24 (16.3)</td>
<td>23 (15.9)</td>
</tr>
<tr>
<td>Non-hilar CC</td>
<td>61 (17.9)</td>
<td>28 (19)</td>
<td>25 (17.2)</td>
</tr>
<tr>
<td>Gallbladder cancer</td>
<td>103 (30.3)</td>
<td>47 (32)</td>
<td>45 (31)</td>
</tr>
<tr>
<td>Ampullary cancer</td>
<td>33 (9.7)</td>
<td>18 (12.2)</td>
<td>15 (10.3)</td>
</tr>
<tr>
<td>BMI</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>≥ 18.5</td>
<td>309 (92.0)</td>
<td>140 (96.6)</td>
<td>131 (90.3)</td>
</tr>
<tr>
<td>&lt; 18.5</td>
<td>27 (8.0)</td>
<td>5 (3.4)</td>
<td>14 (9.7)</td>
</tr>
<tr>
<td>WBC count (×μL)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Normal (&lt;10,800)</td>
<td>262 (77.3)</td>
<td>134 (91.2)</td>
<td>117 (80.7)</td>
</tr>
<tr>
<td>Abnormal (≥10,800)</td>
<td>77 (22.7)</td>
<td>13 (8.8)</td>
<td>28 (19.3)</td>
</tr>
<tr>
<td>Hemoglobin (g/dL)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Normal (≥12)</td>
<td>278 (82.0)</td>
<td>144 (98.0)</td>
<td>112 (77.2)</td>
</tr>
<tr>
<td>Abnormal (&lt;12)</td>
<td>61 (18.0)</td>
<td>3 (2.0)</td>
<td>33 (22.8)</td>
</tr>
<tr>
<td>Platelet (×10^3/μL)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Normal (≥150)</td>
<td>182 (53.7)</td>
<td>99 (67.3)</td>
<td>71 (49)</td>
</tr>
<tr>
<td>Abnormal (&lt;150)</td>
<td>157 (46.3)</td>
<td>48 (32.7)</td>
<td>74 (51)</td>
</tr>
<tr>
<td>Protein (g/dL)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Normal (≥ 6.9)</td>
<td>189 (55.8)</td>
<td>96 (65.3)</td>
<td>74 (51)</td>
</tr>
<tr>
<td>Abnormal (&lt; 6.9)</td>
<td>150 (44.2)</td>
<td>51 (34.7)</td>
<td>71 (49)</td>
</tr>
<tr>
<td>Albumin (g/dL)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Normal (≥ 3.4)</td>
<td>300 (88.5)</td>
<td>139 (94.6)</td>
<td>124 (85.5)</td>
</tr>
</tbody>
</table>

Note: Parentheses indicate percentages.
<table>
<thead>
<tr>
<th>Abnormal (&lt; 3.4)</th>
<th>Normal (&lt; 23)</th>
<th>Abnormal (≥ 23)</th>
<th>Abnormal (≥ 33)</th>
<th>Normal (&lt; 12)</th>
<th>Abnormal (≥ 12)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>BUN (mg/dL)</strong></td>
<td>Normal (&lt; 23)</td>
<td>Abnormal (≥ 23)</td>
<td>Abnormal (≥ 33)</td>
<td>BUN (mg/dL)</td>
<td>ALP (IU/L)</td>
</tr>
<tr>
<td>39 (11.5)</td>
<td>143 (42.2)</td>
<td>196 (57.8)</td>
<td>162 (47.8)</td>
<td>214 (64.7)</td>
<td>112 (35.2)</td>
</tr>
<tr>
<td>8 (5.4)</td>
<td>87 (25.9)</td>
<td>60 (17.0)</td>
<td>56 (17.0)</td>
<td>82 (24.9)</td>
<td>35 (11.6)</td>
</tr>
<tr>
<td>21 (14.5)</td>
<td>50 (15.0)</td>
<td>95 (27.6)</td>
<td>79 (23.1)</td>
<td>15 (4.5)</td>
<td>28 (8.5)</td>
</tr>
<tr>
<td>9 (20.9)</td>
<td>5 (11.6)</td>
<td>38 (11.6)</td>
<td>26 (7.7)</td>
<td>&lt; 0.001</td>
<td>&lt; 0.001</td>
</tr>
<tr>
<td><strong>AST (IU/L)</strong></td>
<td>Normal (&lt; 30)</td>
<td>Abnormal (≥ 30)</td>
<td>Abnormal (≥ 33)</td>
<td>AST (IU/L)</td>
<td>177 (52.2)</td>
</tr>
<tr>
<td>134 (39.5)</td>
<td>205 (60.5)</td>
<td>162 (47.8)</td>
<td>17 (39.5)</td>
<td>212 (62.7)</td>
<td></td>
</tr>
<tr>
<td>75 (51.0)</td>
<td>72 (49.0)</td>
<td>56 (38.1)</td>
<td>91 (61.9)</td>
<td>112 (76.2)</td>
<td></td>
</tr>
<tr>
<td>49 (33.8)</td>
<td>96 (66.2)</td>
<td>79 (54.5)</td>
<td>66 (45.5)</td>
<td>82 (56.9)</td>
<td></td>
</tr>
<tr>
<td>8 (18.6)</td>
<td>35 (81.4)</td>
<td>26 (60.6)</td>
<td>17 (39.5)</td>
<td>15 (34.9)</td>
<td></td>
</tr>
<tr>
<td><strong>ALT (IU/L)</strong></td>
<td>Normal (&lt; 33)</td>
<td>Abnormal (≥ 33)</td>
<td>Abnormal (≥ 123)</td>
<td>ALT (IU/L)</td>
<td>303 (89.7)</td>
</tr>
<tr>
<td>177 (52.2)</td>
<td>162 (47.8)</td>
<td>35 (10.3)</td>
<td>35 (10.3)</td>
<td>212 (62.7)</td>
<td></td>
</tr>
<tr>
<td>91 (61.9)</td>
<td>56 (38.1)</td>
<td>15 (10.2)</td>
<td>15 (10.2)</td>
<td>112 (76.2)</td>
<td></td>
</tr>
<tr>
<td>66 (45.5)</td>
<td>79 (54.5)</td>
<td>13 (9.0)</td>
<td>13 (9.0)</td>
<td>82 (56.9)</td>
<td></td>
</tr>
<tr>
<td>17 (39.5)</td>
<td>26 (60.6)</td>
<td>6 (14.0)</td>
<td>6 (14.0)</td>
<td>15 (34.9)</td>
<td></td>
</tr>
<tr>
<td><strong>Bilirubin (mg/dL)</strong></td>
<td>Normal (&lt; 1.2)</td>
<td>Abnormal (≥ 1.2)</td>
<td>ALP (IU/L)</td>
<td>Bilirubin (mg/dL)</td>
<td></td>
</tr>
<tr>
<td>212 (62.7)</td>
<td>126 (37.3)</td>
<td>304 (89.7)</td>
<td>95 (28.1)</td>
<td>Normal (&lt; 139)</td>
<td></td>
</tr>
<tr>
<td>112 (76.2)</td>
<td>35 (23.8)</td>
<td>132 (89.8)</td>
<td>35 (23.8)</td>
<td>95 (28.1)</td>
<td></td>
</tr>
<tr>
<td>82 (56.9)</td>
<td>62 (43.1)</td>
<td>132 (91.0)</td>
<td>37 (25.7)</td>
<td>37 (25.7)</td>
<td></td>
</tr>
<tr>
<td>15 (34.9)</td>
<td>28 (65.1)</td>
<td>37 (86.0)</td>
<td>21 (48.8)</td>
<td>21 (48.8)</td>
<td></td>
</tr>
<tr>
<td><strong>Cholesterol (mg/dL)</strong></td>
<td>Abnormal (≥ 123)</td>
<td>Abnormal (≥ 123)</td>
<td>Abnormal (≥ 123)</td>
<td>Normal (&lt; 139)</td>
<td></td>
</tr>
<tr>
<td>35 (10.3)</td>
<td>212 (62.7)</td>
<td>243 (71.9)</td>
<td>95 (28.1)</td>
<td>304 (89.7)</td>
<td></td>
</tr>
<tr>
<td>15 (10.2)</td>
<td>112 (76.2)</td>
<td>112 (46.2)</td>
<td>35 (23.8)</td>
<td>132 (89.8)</td>
<td></td>
</tr>
<tr>
<td>13 (9.0)</td>
<td>107 (74.3)</td>
<td>107 (74.3)</td>
<td>37 (25.7)</td>
<td>132 (91.0)</td>
<td></td>
</tr>
<tr>
<td>6 (14.0)</td>
<td>22 (51.2)</td>
<td>22 (51.2)</td>
<td>21 (48.8)</td>
<td>37 (86.0)</td>
<td></td>
</tr>
<tr>
<td><strong>CEA (ng/mL)</strong></td>
<td>&lt; 9</td>
<td>≥ 9</td>
<td>&lt; 9</td>
<td>CEA (ng/mL)</td>
<td></td>
</tr>
<tr>
<td>231 (69)</td>
<td>104 (31)</td>
<td>231 (69)</td>
<td>104 (31)</td>
<td>&lt; 9</td>
<td></td>
</tr>
<tr>
<td>119 (81)</td>
<td>28 (19)</td>
<td>119 (81)</td>
<td>28 (19)</td>
<td>≥ 9</td>
<td></td>
</tr>
<tr>
<td>102 (70.3)</td>
<td>43 (29.7)</td>
<td>102 (70.3)</td>
<td>43 (29.7)</td>
<td>&lt; 0.001</td>
<td></td>
</tr>
<tr>
<td>10 (23.3)</td>
<td>33 (76.7)</td>
<td>10 (23.3)</td>
<td>33 (76.7)</td>
<td>&lt; 0.001</td>
<td></td>
</tr>
<tr>
<td><strong>CA19-9 (U/mL)</strong></td>
<td>&lt; 120</td>
<td>≥ 120</td>
<td>&lt; 120</td>
<td>CA19-9 (U/mL)</td>
<td></td>
</tr>
<tr>
<td>153 (45.1)</td>
<td>186 (54.9)</td>
<td>153 (45.1)</td>
<td>186 (54.9)</td>
<td>&lt; 120</td>
<td></td>
</tr>
<tr>
<td>147 (100)</td>
<td>0</td>
<td>147 (100)</td>
<td>0</td>
<td>≥ 120</td>
<td></td>
</tr>
<tr>
<td>4 (2.8)</td>
<td>141 (97.2)</td>
<td>4 (2.8)</td>
<td>141 (97.2)</td>
<td>&lt; 0.001</td>
<td></td>
</tr>
<tr>
<td>0</td>
<td>43 (100)</td>
<td>0</td>
<td>43 (100)</td>
<td>&lt; 0.001</td>
<td></td>
</tr>
<tr>
<td><strong>NLR</strong></td>
<td>&lt; 3</td>
<td>≥ 3</td>
<td>&lt; 3</td>
<td>NLR</td>
<td></td>
</tr>
<tr>
<td>140 (41.3)</td>
<td>199 (58.7)</td>
<td>140 (41.3)</td>
<td>199 (58.7)</td>
<td>&lt; 3</td>
<td></td>
</tr>
<tr>
<td>104 (70.7)</td>
<td>43 (29.3)</td>
<td>104 (70.7)</td>
<td>43 (29.3)</td>
<td>≥ 3</td>
<td></td>
</tr>
<tr>
<td>25 (17.2)</td>
<td>120 (82.8)</td>
<td>25 (17.2)</td>
<td>120 (82.8)</td>
<td>&lt; 0.001</td>
<td></td>
</tr>
<tr>
<td>11 (25.6)</td>
<td>32 (74.4)</td>
<td>11 (25.6)</td>
<td>32 (74.4)</td>
<td>&lt; 0.001</td>
<td></td>
</tr>
<tr>
<td><strong>PLR</strong></td>
<td>&lt; 150</td>
<td>≥ 150</td>
<td>&lt; 150</td>
<td>PLR</td>
<td></td>
</tr>
<tr>
<td>156 (46.3)</td>
<td>181 (53.7)</td>
<td>156 (46.3)</td>
<td>181 (53.7)</td>
<td>&lt; 150</td>
<td></td>
</tr>
<tr>
<td>89 (60.5)</td>
<td>58 (39.5)</td>
<td>89 (60.5)</td>
<td>58 (39.5)</td>
<td>≥ 150</td>
<td></td>
</tr>
<tr>
<td>64 (44.1)</td>
<td>81 (55.9)</td>
<td>64 (44.1)</td>
<td>81 (55.9)</td>
<td>&lt; 0.001</td>
<td></td>
</tr>
<tr>
<td>3 (7)</td>
<td>44 (93)</td>
<td>3 (7)</td>
<td>44 (93)</td>
<td>&lt; 0.001</td>
<td></td>
</tr>
<tr>
<td><strong>Palliative Tx</strong></td>
<td>No</td>
<td>Gem/Cis</td>
<td>Others a)</td>
<td>Palliative Tx</td>
<td></td>
</tr>
<tr>
<td>106 (31.2)</td>
<td>120 (35.3)</td>
<td>114 (33.5)</td>
<td>106 (31.2)</td>
<td>No</td>
<td></td>
</tr>
<tr>
<td>29 (19.7)</td>
<td>56 (38.1)</td>
<td>62 (42.2)</td>
<td>29 (19.7)</td>
<td>Gem/Cis</td>
<td></td>
</tr>
<tr>
<td>49 (33.8)</td>
<td>53 (36.6)</td>
<td>43 (29.7)</td>
<td>49 (33.8)</td>
<td>53 (36.6)</td>
<td></td>
</tr>
<tr>
<td>25 (58.1)</td>
<td>10 (23.3)</td>
<td>8 (18.6)</td>
<td>25 (58.1)</td>
<td>10 (23.3)</td>
<td></td>
</tr>
</tbody>
</table>

ECOG, Eastern Cooperative Oncology Group; CC, cholangiocarcinoma; BMI, body mass index; WBC, white blood cell; BUN, blood urea nitrogen; AST, aspartate aminotransferase; ALT, alanine aminotransferase; ALP, alkaline phosphatase; CEA, carcinoembryonic antigen; CA 19-9, carbohydrate antigen 19-9; NLR, neutrophil-lymphocyte ratio; PLR, platelet-lymphocyte ratio; Tx, treatment; Gem/Cis, combination chemotherapy with cisplatin and gemcitabine. aFluorouracil or gemcitabine-based (excluding Gem/Cis) chemotherapy.